Cargando…

Placebo-controlled study with OHIO chamber of prophylactic pranlukast for children with Japanese cedar pollinosis: TOPIC-J III study

OBJECTIVE: This double-blind, placebo-controlled comparative study was designed to investigate whether pranlukast dry syrup, a leukotriene receptor antagonist, has a protective effect against priming, controlled pollen exposure, and natural pollen exposure in children with Japanese cedar pollinosis....

Descripción completa

Detalles Bibliográficos
Autores principales: Hosoya, Kei, Masuno, Satoru, Hashiguchi, Kazuhiro, Okubo, Kimihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4937631/
https://www.ncbi.nlm.nih.gov/pubmed/27536454
http://dx.doi.org/10.3109/21556660.2014.960969
_version_ 1782441741745389568
author Hosoya, Kei
Masuno, Satoru
Hashiguchi, Kazuhiro
Okubo, Kimihiro
author_facet Hosoya, Kei
Masuno, Satoru
Hashiguchi, Kazuhiro
Okubo, Kimihiro
author_sort Hosoya, Kei
collection PubMed
description OBJECTIVE: This double-blind, placebo-controlled comparative study was designed to investigate whether pranlukast dry syrup, a leukotriene receptor antagonist, has a protective effect against priming, controlled pollen exposure, and natural pollen exposure in children with Japanese cedar pollinosis. RESEARCH DESIGN AND METHODS: Thirty children aged 12–15 years with Japanese cedar pollinosis (positive skin test for Japanese cedar pollen), who had suffered from pollinosis for at least 2 years and developed severe nasal obstruction when exposed to Japanese cedar pollen, were enrolled in this study. They were randomly allocated to treatment with pranlukast or placebo orally after breakfast and dinner for 8 weeks during the Japanese cedar pollen season. Soon after the start of the pollen season, all subjects underwent a challenge by exposure for 3 h to Japanese cedar pollen (8000 grains/m(3)) in an artificial exposure chamber (OHIO chamber). CLINICAL TRIAL REGISTRATION: The University Hospital Medical Information Network in Japan (UMIN000009840). MAIN OUTCOME MEASURES: The effect of pranlukast was evaluated using self-rating of nasal symptoms by the subjects and measurement of eosinophil cationic protein in nasal discharge specimens. RESULTS: Scores for the symptoms of pollinosis were lower in the pranlukast group than in the placebo group during treatment in the priming state, as well as after controlled pollen exposure and natural pollen exposure. Pranlukast significantly improved the score for nasal obstruction, compared with placebo. A correlation was found between changes of the scores for symptoms of pollinosis and changes of the eosinophil cationic protein level. CONCLUSIONS: These results confirm a protective effect of pranlukast against both priming and challenge (controlled and natural) with Japanese cedar pollen. The present findings suggested that pranlukast dry syrup may be useful for prophylaxis against pollinosis in children.
format Online
Article
Text
id pubmed-4937631
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-49376312016-08-17 Placebo-controlled study with OHIO chamber of prophylactic pranlukast for children with Japanese cedar pollinosis: TOPIC-J III study Hosoya, Kei Masuno, Satoru Hashiguchi, Kazuhiro Okubo, Kimihiro J Drug Assess Original Articles OBJECTIVE: This double-blind, placebo-controlled comparative study was designed to investigate whether pranlukast dry syrup, a leukotriene receptor antagonist, has a protective effect against priming, controlled pollen exposure, and natural pollen exposure in children with Japanese cedar pollinosis. RESEARCH DESIGN AND METHODS: Thirty children aged 12–15 years with Japanese cedar pollinosis (positive skin test for Japanese cedar pollen), who had suffered from pollinosis for at least 2 years and developed severe nasal obstruction when exposed to Japanese cedar pollen, were enrolled in this study. They were randomly allocated to treatment with pranlukast or placebo orally after breakfast and dinner for 8 weeks during the Japanese cedar pollen season. Soon after the start of the pollen season, all subjects underwent a challenge by exposure for 3 h to Japanese cedar pollen (8000 grains/m(3)) in an artificial exposure chamber (OHIO chamber). CLINICAL TRIAL REGISTRATION: The University Hospital Medical Information Network in Japan (UMIN000009840). MAIN OUTCOME MEASURES: The effect of pranlukast was evaluated using self-rating of nasal symptoms by the subjects and measurement of eosinophil cationic protein in nasal discharge specimens. RESULTS: Scores for the symptoms of pollinosis were lower in the pranlukast group than in the placebo group during treatment in the priming state, as well as after controlled pollen exposure and natural pollen exposure. Pranlukast significantly improved the score for nasal obstruction, compared with placebo. A correlation was found between changes of the scores for symptoms of pollinosis and changes of the eosinophil cationic protein level. CONCLUSIONS: These results confirm a protective effect of pranlukast against both priming and challenge (controlled and natural) with Japanese cedar pollen. The present findings suggested that pranlukast dry syrup may be useful for prophylaxis against pollinosis in children. Taylor & Francis 2014-09-03 /pmc/articles/PMC4937631/ /pubmed/27536454 http://dx.doi.org/10.3109/21556660.2014.960969 Text en © 2014 The Author(s). Published by Taylor & Francis http://creativecommons.org/licenses/by/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted.
spellingShingle Original Articles
Hosoya, Kei
Masuno, Satoru
Hashiguchi, Kazuhiro
Okubo, Kimihiro
Placebo-controlled study with OHIO chamber of prophylactic pranlukast for children with Japanese cedar pollinosis: TOPIC-J III study
title Placebo-controlled study with OHIO chamber of prophylactic pranlukast for children with Japanese cedar pollinosis: TOPIC-J III study
title_full Placebo-controlled study with OHIO chamber of prophylactic pranlukast for children with Japanese cedar pollinosis: TOPIC-J III study
title_fullStr Placebo-controlled study with OHIO chamber of prophylactic pranlukast for children with Japanese cedar pollinosis: TOPIC-J III study
title_full_unstemmed Placebo-controlled study with OHIO chamber of prophylactic pranlukast for children with Japanese cedar pollinosis: TOPIC-J III study
title_short Placebo-controlled study with OHIO chamber of prophylactic pranlukast for children with Japanese cedar pollinosis: TOPIC-J III study
title_sort placebo-controlled study with ohio chamber of prophylactic pranlukast for children with japanese cedar pollinosis: topic-j iii study
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4937631/
https://www.ncbi.nlm.nih.gov/pubmed/27536454
http://dx.doi.org/10.3109/21556660.2014.960969
work_keys_str_mv AT hosoyakei placebocontrolledstudywithohiochamberofprophylacticpranlukastforchildrenwithjapanesecedarpollinosistopicjiiistudy
AT masunosatoru placebocontrolledstudywithohiochamberofprophylacticpranlukastforchildrenwithjapanesecedarpollinosistopicjiiistudy
AT hashiguchikazuhiro placebocontrolledstudywithohiochamberofprophylacticpranlukastforchildrenwithjapanesecedarpollinosistopicjiiistudy
AT okubokimihiro placebocontrolledstudywithohiochamberofprophylacticpranlukastforchildrenwithjapanesecedarpollinosistopicjiiistudy